Business Context and Reporting Period
Company: MannKind Corporation (MannKind)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2009
Business Overview: MannKind is a biopharmaceutical company in the development stage, focused on therapeutic products for diabetes and cancer. Its lead product candidate, AFRESA, is an ultra rapid-acting inhaled insulin. In March 2009, the company submitted a New Drug Application (NDA) to the FDA, which was accepted for filing in May 2009. The company has no commercial products and has incurred significant losses since inception.
Key Financial Metrics
| Metric (in thousands) | Six Months Ended June 30, 2009 |
Six Months Ended June 30, 2008 |
|---|---|---|
| Revenue | $0 | $20 |
| Net Loss | $(115,016) | $(151,247) |
| Net Loss Per Share (Basic & Diluted) | $(1.13) | $(1.49) |
| Operating Expenses | $111,192 | $154,949 |
| Research & Development (R&D) | $82,738 | $126,019 |
| General & Administrative (G&A) | $28,454 | $28,930 |
| Cash Used in Operating Activities | $(105,022) | $(140,011) |
| Cash Provided by Financing Activities | $105,450 | $365 |
| Cash and Cash Equivalents (End of Period) | $31,328 | $180,454 |
| Total Debt (Senior Convertible Notes + Related Party) | $247,506 | $142,253 |
Note: All figures are in thousands except per share data. The company reported zero revenue for the six months ended June 30, 2009.
Material Changes vs. Prior Period
- Revenue: The company recognized no revenue in the current period compared to $20,000 in the prior year. No product sales are expected until regulatory approval.
- Net Loss: Net loss decreased by approximately 24% to $115.0 million from $151.2 million, driven primarily by reduced R&D expenses.
- R&D Expenses: Decreased by 34% ($43.3 million) due to the completion of pivotal AFRESA trials in 2008, reduced manufacturing costs, and a reduction in force in April 2009.
- Debt: Total liabilities increased significantly due to borrowings under a related-party loan arrangement. The outstanding balance on this note rose from $30.0 million to $135.0 million during the period.
- Cash Position: Cash and cash equivalents decreased from $27.6 million at year-end 2008 to $31.3 million at June 30, 2009, despite a net increase in cash of $3.7 million during the quarter, largely offset by the drawdown of marketable securities.
Guidance, Outlook, and Risks
Outlook and Liquidity: Management believes existing capital resources, consisting of approximately $34.0 million in cash and marketable securities plus $215.0 million available under a related-party loan facility, will fund operations through the second quarter of 2010. However, the company explicitly states it will need to raise additional capital through equity/debt sales or strategic collaborations to continue development and commercialization. There is substantial doubt about the company's ability to continue as a going concern if additional funding is not secured.
Management Commentary: The company is focused on the FDA review of the AFRESA NDA. R&D expenses are expected to continue decreasing in 2009 compared to the prior year due to the completion of pivotal trials and facility expansion. G&A expenses are expected to increase slightly due to professional fees related to a recent asset purchase from Pfizer.
Risks and Contingencies:
- Regulatory Risk: AFRESA is not yet approved. The FDA is reviewing it as a "combination product" (drug and device), which may lengthen the review process. The FDA has also questioned the trade name "AFRESA" for potential confusion with other drugs.
- Capital Risk: The company has an accumulated deficit of $1.5 billion and a stockholders' equity deficit of $19.3 million. Failure to raise capital could force a curtailment of projects.
- Related-Party Loan: A significant portion of liquidity depends on a $350 million credit facility with an entity controlled by the principal stockholder. The lender can require prepayment of up to $200 million after January 1, 2010.
- Supply Chain: The company relies on third-party suppliers for insulin and inhaler components. Failure of suppliers to meet regulatory standards could delay commercialization.
Investor Verification Checklist
- Capital Runway: Verify the sufficiency of the $34 million cash balance and the $215 million available credit line to sustain operations through Q2 2010 without dilution or additional debt.
- FDA Status: Monitor the FDA's review timeline for the AFRESA NDA and any requests for additional data or changes to the trade name.
- Related-Party Loan Terms: Review the terms of the loan with The Mann Group LLC, specifically the prepayment clause effective January 1, 2010, and the interest rate structure (LIBOR + 3%).
- Supply Agreements: Confirm the status of the insulin supply agreement with Organon N.V. and the recent asset purchase from Pfizer regarding bulk insulin inventory.
- Going Concern: Assess the likelihood of securing strategic collaborations or additional financing given the current market conditions and the company's accumulated deficit.